Biomaterial Database

Single case study. Amoxapine, a new antidepressant, appears in human milk. 1979

A J Gelenberg

A young woman developed galactorrhea during treatment with a new dibenzoxazepine antidepressant, amoxapine. Both amoxapine and its active and major metabolite, 8-OH-amoxapine, appeared in breast milk. More recent literature suggests that probably all antidepressants can appear in human milk.

UI	MeSH Term	Description	Entries
D008895	Milk, Human	Milk that is produced by HUMAN MAMMARY GLANDS.	Breast Milk,Human Milk,Milk, Breast
D011247	Pregnancy	The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	Gestation,Pregnancies
D003863	Depression	Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.	Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003989	Dibenzoxazepines
D005260	Female		Females
D005687	Galactorrhea	Excessive or inappropriate LACTATION in females or males, and not necessarily related to PREGNANCY. Galactorrhea can occur either unilaterally or bilaterally, and be profuse or sparse. Its most common cause is HYPERPROLACTINEMIA.	Galactorrheas
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000657	Amoxapine	The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.	2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine,Asendin,Asendis,CL-67,772,Demolox,Desmethylloxapine,Défanyl,CL 67,772,CL67,772
D001711	Biotransformation	The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.